NEW YORK — In his first public comments, Pfizer’s new innovation chief — once a Wall Street analyst skeptical of the company — said he was confident in the company’s obesity plans and ...

Please watch the video at Investors.com - How To Buy Stocks: Flat Base Chart Pattern Previously, Pfizer only identified two of its obesity treating ... Pfizer plans to block the activity of ...

There’s no question, however, that the decision to abandon the twice-daily version introduces a significant delay to Pfizer’s plans to enter the obesity market, which has been transformed in ...

Pfizer (NYSE:PFE) has named James List, a former Johnson & Johnson (NYSE:JNJ) executive, as the company’s new chief internal medicine officer to boost the company's efforts in obesity drug ...

March 6 (Reuters) - Pfizer (PFE.N), opens new tab on Thursday ... in January it would go "all in" to develop its experimental obesity drug, danuglipron, recruiting more experts in the area to ...

The anticipation surrounding dose optimization data for Pfizer's obesity treatment ... due to the study's structure and disclosure plans. With a solid financial health score of "GOOD" from ...

Both deputy directors at the key FDA center that oversees regulation of cancer drugs plan on leaving the agency ...

In vaccines, Pfizer plans to start a Phase 3 study for PCV ... study is critical for Pfizer’s entry into the lucrative obesity market. It is still in progress, with data expected in Q1-CY25.

For Lilly, the main driver behind LillyDirect has been seen as Zepbound, which, as an obesity drug ... market battle with GSK's Arexvy. Pfizer has said it plans to expand the medicines and ...

In his first public comments, Pfizer’s new innovation chief — once a Wall Street analyst skeptical of the company — said he was confident in the company’s obesity plans and shed light on ...